Characteristics of patients with R/R B-ALL with CNSL at baseline (N = 48)
| Characteristic . | Value . |
|---|---|
| Median age (range), y | 31 (6-68) |
| Age group, y | |
| <40 | 32 (66.7) |
| ≥40 | 16 (33.3) |
| Sex | |
| Male | 30 (62.5) |
| Female | 18 (37.5) |
| Disease status | |
| BM + CNS | 36 (75.0) |
| Isolated CNS | 12 (25.0) |
| Other EMDs* | |
| Yes | 9 (18.8) |
| No | 39 (81.2) |
| Poor-risk cytogenetics† | |
| Ph+‡ | 20 (41.7) |
| T315I mutation | 3 (6.3) |
| FLT3/ITD mutation | 1 (2.1) |
| IKZF1 mutation | 3 (6.3) |
| Ph-like§ǁ | 3 (9.1) |
| TP53 aberrationǁ | 2 (6.1) |
| MLL rearrangementǁ | 4 (12.2) |
| Complex karyotype‡ | 2 (4.2) |
| BM blasts before infusion, % | |
| <5 | 22 (45.8) |
| ≥5 | 26 (54.2) |
| CNS status before infusion | |
| 1 | 3 (6.3) |
| 2 | 15 (31.2) |
| 3 | 30 (62.5) |
| Median prior treatment lines (range), n | 4 (3-16) |
| No. of relapses | |
| 1 | 25 (52.1) |
| 2 | 13 (27.1) |
| ≥3 | 6 (12.5) |
| Primary refractory¶ | 4 (8.3)* |
| Prior allo-HSCT | |
| Yes | 10 (20.8) |
| No | 38 (79.2) |
| Prior cranial irradiation | |
| Yes | 5 (10.4) |
| No | 43 (89.6) |
| CNS-directed bridging treatment | |
| Yes | 27 (56.3) |
| No | 21 (43.7) |
| Costimulator | |
| 4-1BB | 32 (66.7) |
| CD28 | 5 (10.4) |
| CD28 + 4-1BB | 11 (22.9) |
| Infused cells | |
| Isolated CD19 | 37 (77.1) |
| Combined CD19 + CD22 | 11 (22.9) |
| Average dose, ×106/kg | |
| <3 | 26 (54.2) |
| 3-5 | 13 (27.0) |
| >5 | 9 (18.8) |
| Characteristic . | Value . |
|---|---|
| Median age (range), y | 31 (6-68) |
| Age group, y | |
| <40 | 32 (66.7) |
| ≥40 | 16 (33.3) |
| Sex | |
| Male | 30 (62.5) |
| Female | 18 (37.5) |
| Disease status | |
| BM + CNS | 36 (75.0) |
| Isolated CNS | 12 (25.0) |
| Other EMDs* | |
| Yes | 9 (18.8) |
| No | 39 (81.2) |
| Poor-risk cytogenetics† | |
| Ph+‡ | 20 (41.7) |
| T315I mutation | 3 (6.3) |
| FLT3/ITD mutation | 1 (2.1) |
| IKZF1 mutation | 3 (6.3) |
| Ph-like§ǁ | 3 (9.1) |
| TP53 aberrationǁ | 2 (6.1) |
| MLL rearrangementǁ | 4 (12.2) |
| Complex karyotype‡ | 2 (4.2) |
| BM blasts before infusion, % | |
| <5 | 22 (45.8) |
| ≥5 | 26 (54.2) |
| CNS status before infusion | |
| 1 | 3 (6.3) |
| 2 | 15 (31.2) |
| 3 | 30 (62.5) |
| Median prior treatment lines (range), n | 4 (3-16) |
| No. of relapses | |
| 1 | 25 (52.1) |
| 2 | 13 (27.1) |
| ≥3 | 6 (12.5) |
| Primary refractory¶ | 4 (8.3)* |
| Prior allo-HSCT | |
| Yes | 10 (20.8) |
| No | 38 (79.2) |
| Prior cranial irradiation | |
| Yes | 5 (10.4) |
| No | 43 (89.6) |
| CNS-directed bridging treatment | |
| Yes | 27 (56.3) |
| No | 21 (43.7) |
| Costimulator | |
| 4-1BB | 32 (66.7) |
| CD28 | 5 (10.4) |
| CD28 + 4-1BB | 11 (22.9) |
| Infused cells | |
| Isolated CD19 | 37 (77.1) |
| Combined CD19 + CD22 | 11 (22.9) |
| Average dose, ×106/kg | |
| <3 | 26 (54.2) |
| 3-5 | 13 (27.0) |
| >5 | 9 (18.8) |
Data are presented as n (%) unless otherwise specified.
Extramedullary diseases other than CNS involvement.
From cytogenetic analysis performed at any time after diagnosis; some patients had >1 abnormality identified. All patients were screened for cytogenetic abnormalities using karyotyping, and 33 patients underwent next-generation sequencing covering gene fusions and pathogenic mutations recommended by National Comprehensive Cancer Network guidelines.
Screening assessment in 48 patients.
Including 3 Ph− patients with EBF1-PDGFRB+ fusion (n = 2) and JAK2/PAX5 rearrangement (n = 1).
Screening assessment in 33 patients.
Patients experiencing less than CR after initial induction therapy.